Finding. A neuronal plasticity coactivator splits Group 3 β medulloblastoma into a longer-lived, mitochondrially quieter half and a shorter-lived, mitochondrially louder half. Vanini, Roesler and colleagues find CREB-regulated transcription coactivator 1 (CRTC1) throughout developing cerebellum, highest among pediatric brain tumors in medulloblastoma, and highest among medulloblastoma groups in Group 4. The survival association is narrower. Only Group 3 β patients with high CRTC1 live longer, and that still holds after the authors correct across all 12 molecular subtypes. Inside Group 3 β, CRTC1 expression runs inverse to oxidative phosphorylation, mitochondrial organization, and mitochondrial translation signatures. High and low tumors also differ in microenvironment-related transcriptional marks.
Why this paper matters
Group 3 β is where you want a marker. A gene that is both a survival split and an anti-mitochondrial-program split is a hypothesis you can take into a dish: is the mitochondrial-high / CRTC1-low state the aggressive bioenergetic one? The paper does not close that loop. It is still the right loop to write down.
Do not flatten the geography. Group 4 wears the most CRTC1 and is not the survival story. Group 3 β wears the correlation.
What they actually measured
Public developmental and tumor transcriptomes, group/subtype contrasts, a multiple-testing-aware survival analysis, and pathway enrichment inside Group 3 β. No CRTC1 knockdown, no Seahorse, no mitoribosome western.
How to read the score
Mid 80s. Subtype-restricted survival plus a mitochondrial-translation anti-correlation. Confidence is medium: RNA, not function.
Caveats
Signature inverse is not causation. Batch effects in public MB datasets are legendary. Microenvironment associations are selected, not a full deconvolution paper.
What to do with it
Score CRTC1 against KEGG/GO mitochondrial-translation sets in Group 3 β only. If you have a Group 3 β model, knock CRTC1 and ask whether OXPHOS gene sets and growth move together. Do not add CRTC1 to a clinical panel from this brief.